{"product_id":"wc-0efe51bcb5f34c14-50447","title":"SCAI Scientific Sessions 2026 – Videos + PPTs","description":"\u003ch1 data-pm-slice=\"1 1 []\"\u003eSociety for Cardiovascular Angiography \u0026amp; Interventions Scientific Sessions 2026\u003c\/h1\u003e\r\n\u003ch2\u003eSCAI Scientific Sessions 2026 | Interventional Cardiology, Complex PCI, Coronary Intervention, TAVR, Structural Heart Disease, Peripheral Vascular Interventions \u0026amp; Late-Breaking Clinical Trials\u003c\/h2\u003e\r\nThe \u003cstrong\u003eSCAI Scientific Sessions 2026 – Videos + PPTs\u003c\/strong\u003e provides a comprehensive educational overview of contemporary interventional cardiology, featuring scientific research, clinical developments, advanced procedural techniques, and multidisciplinary cardiovascular care.\r\n\r\nOrganized by the \u003cstrong\u003eSociety for Cardiovascular Angiography \u0026amp; Interventions (SCAI)\u003c\/strong\u003e in collaboration with the Canadian Association of Interventional Cardiology (CAIC-ACCI), the 2026 meeting brought together interventional cardiologists, cardiovascular researchers, physicians, fellows, and catheterization laboratory professionals from around the world.\r\n\r\nHeld \u003cstrong\u003eApril 23–25, 2026\u003c\/strong\u003e, at the Palais des Congrès de Montréal in Montreal, Canada, the scientific meeting featured expert presentations, late-breaking clinical trials, case-based discussions, live procedural demonstrations, research abstracts, and advanced education across coronary, structural, peripheral, and congenital cardiovascular interventions.\r\n\r\nThe \u003cstrong\u003eSCAI 2026 Scientific Sessions\u003c\/strong\u003e program examines evolving clinical practices involving complex percutaneous coronary intervention (PCI), intravascular imaging, coronary physiology, cardiogenic shock, calcified coronary disease, transcatheter valve interventions, peripheral artery disease, critical limb-threatening ischemia, congenital heart interventions, and cardiovascular device innovation.\r\n\r\nThe original conference also addressed procedural safety, complications management, emerging clinical research, leadership, multidisciplinary decision-making, and developments in cardiovascular technology.\r\n\r\nThe educational collection is described as including \u003cstrong\u003evideo presentations and PowerPoint slides (PPTs)\u003c\/strong\u003e associated with the SCAI Scientific Sessions 2026 program.\r\n\u003ch2\u003eCourse Details\u003c\/h2\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCourse:\u003c\/strong\u003e Society for Cardiovascular Angiography \u0026amp; Interventions Scientific Sessions 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eShort Title:\u003c\/strong\u003e SCAI Scientific Sessions 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOfficial Event:\u003c\/strong\u003e SCAI 2026 Scientific Sessions \u0026amp; CAIC-ACCI Summit\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOrganizer:\u003c\/strong\u003e Society for Cardiovascular Angiography \u0026amp; Interventions (SCAI)\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003ePartner Organization:\u003c\/strong\u003e Canadian Association of Interventional Cardiology (CAIC-ACCI)\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eDates:\u003c\/strong\u003e April 23–25, 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLocation:\u003c\/strong\u003e Montreal, Quebec, Canada\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eVenue:\u003c\/strong\u003e Palais des Congrès de Montréal\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eVenue Address:\u003c\/strong\u003e 201 Avenue Viger Ouest, Montréal, QC H2Z 1X7\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOfficial Event Format:\u003c\/strong\u003e In-Person Scientific Conference\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eListed Educational Format:\u003c\/strong\u003e Videos + PowerPoint Presentations\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003ePrimary Specialty:\u003c\/strong\u003e Interventional Cardiology\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eAdditional Focus:\u003c\/strong\u003e General Cardiology, Structural Heart Disease, Coronary Intervention, Peripheral Vascular Medicine, Congenital Cardiology and Endovascular Medicine\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLanguage:\u003c\/strong\u003e English\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eScientific Program:\u003c\/strong\u003e More Than 80 Sessions Across Multiple Educational Tracks\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eMain Program Chair:\u003c\/strong\u003e Sahil A. Parikh, MD, FSCAI\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eAssociate Program Chair:\u003c\/strong\u003e Andrew J. Klein, MD, FSCAI\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eAssistant Program Chair:\u003c\/strong\u003e Frederick G. P. Welt, MD, MSc, FSCAI\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe original conference included more than 500 faculty members and more than 810 scientific abstracts.\r\n\r\nThese figures describe the original SCAI meeting and do not establish the exact number of recordings, presentations, or files included in the MedicalAmboss product.\r\n\u003ch2\u003ePackage Includes\u003c\/h2\u003e\r\n\u003cstrong\u003eListed Content Format: Videos + PPTs\u003c\/strong\u003e\r\n\r\nThe product is described as including:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eEducational Video Presentations\u003c\/li\u003e\r\n \t\u003cli\u003ePowerPoint Presentation Materials\u003c\/li\u003e\r\n \t\u003cli\u003eInterventional Cardiology Educational Content\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Research Discussions\u003c\/li\u003e\r\n \t\u003cli\u003eProcedural and Scientific Updates\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eImportant:\u003c\/strong\u003e The exact number of videos, PPT files, and included conference sessions has not been independently verified.\r\n\r\nThe original SCAI Conference Library and official member access are separate from this MedicalAmboss listing.\r\n\u003ch2\u003eTarget Audience\u003c\/h2\u003e\r\nThe program is intended for healthcare professionals involved in cardiovascular diagnosis, catheter-based interventions, advanced procedural care, and cardiovascular research.\r\n\r\nThe target audience includes:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eInterventional Cardiologists\u003c\/li\u003e\r\n \t\u003cli\u003eGeneral Cardiologists\u003c\/li\u003e\r\n \t\u003cli\u003eInvasive Cardiologists\u003c\/li\u003e\r\n \t\u003cli\u003eStructural Heart Intervention Specialists\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary Intervention Specialists\u003c\/li\u003e\r\n \t\u003cli\u003ePeripheral Vascular Intervention Specialists\u003c\/li\u003e\r\n \t\u003cli\u003eCongenital Heart Disease Specialists\u003c\/li\u003e\r\n \t\u003cli\u003ePediatric Interventional Cardiologists\u003c\/li\u003e\r\n \t\u003cli\u003eCardiology Fellows\u003c\/li\u003e\r\n \t\u003cli\u003eInterventional Cardiology Fellows\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Researchers\u003c\/li\u003e\r\n \t\u003cli\u003eCath Lab Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eCardiac Catheterization Laboratory Nurses\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Nurse Practitioners\u003c\/li\u003e\r\n \t\u003cli\u003ePhysician Assistants\u003c\/li\u003e\r\n \t\u003cli\u003eRadiologic Technologists\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Technologists\u003c\/li\u003e\r\n \t\u003cli\u003eEndovascular Specialists\u003c\/li\u003e\r\n \t\u003cli\u003eOther Healthcare Professionals Involved in Interventional Cardiology\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe program is particularly relevant to specialists seeking updates on emerging cardiovascular interventions, new procedural techniques, clinical research, and complex case management.\r\n\u003ch2\u003eProgram Overview\u003c\/h2\u003e\r\nInterventional cardiology continues to evolve through developments in catheter-based devices, cardiovascular imaging, physiological assessment, clinical trials, and minimally invasive treatment strategies.\r\n\r\nThe \u003cstrong\u003eSCAI 2026 Scientific Sessions \u0026amp; CAIC-ACCI Summit\u003c\/strong\u003e addresses these developments through five major clinical and professional tracks:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCongenital Heart Intervention\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary Intervention\u003c\/li\u003e\r\n \t\u003cli\u003ePeripheral Vascular Intervention\u003c\/li\u003e\r\n \t\u003cli\u003eStructural Heart Intervention\u003c\/li\u003e\r\n \t\u003cli\u003eInterventional Leadership\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nAdditional educational activities include late-breaking clinical trials, scientific research presentations, live cases, advanced workshops, clinical case exchanges, and professional development sessions.\r\n\r\nThe curriculum covers:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eComplex Percutaneous Coronary Intervention\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary Artery Disease\u003c\/li\u003e\r\n \t\u003cli\u003eCalcified Coronary Lesions\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary Intravascular Imaging\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary Physiology\u003c\/li\u003e\r\n \t\u003cli\u003eDrug-Eluting Stents\u003c\/li\u003e\r\n \t\u003cli\u003eIn-Stent Restenosis\u003c\/li\u003e\r\n \t\u003cli\u003eCardiogenic Shock\u003c\/li\u003e\r\n \t\u003cli\u003eAcute Myocardial Infarction\u003c\/li\u003e\r\n \t\u003cli\u003eMechanical Circulatory Support\u003c\/li\u003e\r\n \t\u003cli\u003eAntiplatelet Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eStructural Heart Disease\u003c\/li\u003e\r\n \t\u003cli\u003eTranscatheter Aortic Valve Replacement\u003c\/li\u003e\r\n \t\u003cli\u003eTranscatheter Mitral Valve Replacement\u003c\/li\u003e\r\n \t\u003cli\u003eMitral Transcatheter Edge-to-Edge Repair\u003c\/li\u003e\r\n \t\u003cli\u003ePeripheral Artery Disease\u003c\/li\u003e\r\n \t\u003cli\u003eCritical Limb-Threatening Ischemia\u003c\/li\u003e\r\n \t\u003cli\u003eEndovascular Revascularization\u003c\/li\u003e\r\n \t\u003cli\u003ePulmonary Embolism Intervention\u003c\/li\u003e\r\n \t\u003cli\u003eCongenital Heart Interventions\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Device Development\u003c\/li\u003e\r\n \t\u003cli\u003eProcedural Complications\u003c\/li\u003e\r\n \t\u003cli\u003eLate-Breaking Clinical Trials\u003c\/li\u003e\r\n \t\u003cli\u003eScientific Research\u003c\/li\u003e\r\n \t\u003cli\u003eInterventional Cardiology Leadership\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe educational focus is on integrating scientific evidence with procedural expertise and patient-centered cardiovascular decision-making.\r\n\u003ch2\u003eLearning Objectives\u003c\/h2\u003e\r\nBased on the major educational themes of the SCAI 2026 meeting, learners reviewing the program should be better prepared to:\r\n\u003col start=\"1\" data-spread=\"true\"\u003e\r\n \t\u003cli\u003eReview contemporary clinical research relevant to interventional cardiology.\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate emerging evidence involving coronary, structural, peripheral, and congenital cardiovascular interventions.\u003c\/li\u003e\r\n \t\u003cli\u003eUnderstand the role of advanced coronary imaging and physiological assessment in procedural planning.\u003c\/li\u003e\r\n \t\u003cli\u003eExamine treatment strategies for complex coronary artery disease and calcified coronary lesions.\u003c\/li\u003e\r\n \t\u003cli\u003eReview contemporary approaches to cardiogenic shock and mechanical circulatory support.\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate transcatheter treatment strategies for valvular and structural heart disease.\u003c\/li\u003e\r\n \t\u003cli\u003eReview endovascular approaches to peripheral artery disease and critical limb-threatening ischemia.\u003c\/li\u003e\r\n \t\u003cli\u003eAnalyze emerging clinical trial results and their potential implications for cardiovascular practice.\u003c\/li\u003e\r\n \t\u003cli\u003eApply structured clinical reasoning to complex procedural cases.\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize important procedural complications and review relevant prevention and management principles.\u003c\/li\u003e\r\n \t\u003cli\u003eUnderstand developments in congenital heart interventions and multidisciplinary cardiovascular care.\u003c\/li\u003e\r\n \t\u003cli\u003eExplore leadership, professional development, and collaboration within interventional cardiology.\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eOfficial 2026 Scientific Program Tracks\u003c\/h1\u003e\r\n\u003ch2\u003eSession I – Coronary Intervention\u003c\/h2\u003e\r\nThe Coronary Track focuses on contemporary percutaneous coronary intervention, complex coronary anatomy, advanced imaging, physiology, and procedural decision-making.\r\n\u003ch3\u003eAdvanced Coronary Imaging and Physiology\u003c\/h3\u003e\r\nReviews the role of intravascular imaging and coronary physiological assessment in modern PCI.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eIntravascular Ultrasound\u003c\/li\u003e\r\n \t\u003cli\u003eOptical Coherence Tomography\u003c\/li\u003e\r\n \t\u003cli\u003eFractional Flow Reserve\u003c\/li\u003e\r\n \t\u003cli\u003eInstantaneous Wave-Free Ratio\u003c\/li\u003e\r\n \t\u003cli\u003eLesion Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eStent Optimization\u003c\/li\u003e\r\n \t\u003cli\u003eProcedural Planning\u003c\/li\u003e\r\n \t\u003cli\u003ePhysiological Guidance\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Decision-Making\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eComplex Calcified Coronary Artery Disease\u003c\/h3\u003e\r\nExamines interventional approaches to complex calcified coronary lesions.\r\n\r\nImportant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCoronary Calcification\u003c\/li\u003e\r\n \t\u003cli\u003eLesion Preparation\u003c\/li\u003e\r\n \t\u003cli\u003eRotational Atherectomy\u003c\/li\u003e\r\n \t\u003cli\u003eIntravascular Lithotripsy\u003c\/li\u003e\r\n \t\u003cli\u003eCutting Balloons\u003c\/li\u003e\r\n \t\u003cli\u003eScoring Balloons\u003c\/li\u003e\r\n \t\u003cli\u003eComplex PCI\u003c\/li\u003e\r\n \t\u003cli\u003eProcedural Complications\u003c\/li\u003e\r\n \t\u003cli\u003eDevice Selection\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eContemporary Management of In-Stent Restenosis\u003c\/h3\u003e\r\nReviews diagnostic assessment and treatment considerations for coronary in-stent restenosis.\r\n\r\nRelevant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eIn-Stent Restenosis\u003c\/li\u003e\r\n \t\u003cli\u003eDrug-Eluting Stents\u003c\/li\u003e\r\n \t\u003cli\u003eDrug-Coated Balloons\u003c\/li\u003e\r\n \t\u003cli\u003eIntravascular Imaging\u003c\/li\u003e\r\n \t\u003cli\u003eMechanical Stent Failure\u003c\/li\u003e\r\n \t\u003cli\u003eNeoatherosclerosis\u003c\/li\u003e\r\n \t\u003cli\u003eRepeat Revascularization\u003c\/li\u003e\r\n \t\u003cli\u003eProcedural Optimization\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eCardiogenic Shock and Acute Coronary Syndromes\u003c\/h3\u003e\r\nThe coronary curriculum also addresses difficult decisions involving acute myocardial infarction and cardiogenic shock.\r\n\r\nImportant subjects include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAcute Myocardial Infarction\u003c\/li\u003e\r\n \t\u003cli\u003eCardiogenic Shock\u003c\/li\u003e\r\n \t\u003cli\u003eHemodynamic Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eMechanical Circulatory Support\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary Revascularization\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Risk Stratification\u003c\/li\u003e\r\n \t\u003cli\u003eMultidisciplinary Shock Teams\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Outcomes\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eSession II – Structural Heart Intervention\u003c\/h2\u003e\r\nThe Structural Heart Track explores minimally invasive catheter-based approaches to structural and valvular heart disease.\r\n\u003ch3\u003eTranscatheter Aortic Valve Replacement\u003c\/h3\u003e\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAortic Stenosis\u003c\/li\u003e\r\n \t\u003cli\u003eTAVR\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Selection\u003c\/li\u003e\r\n \t\u003cli\u003eValve Sizing\u003c\/li\u003e\r\n \t\u003cli\u003eProcedural Planning\u003c\/li\u003e\r\n \t\u003cli\u003eVascular Access\u003c\/li\u003e\r\n \t\u003cli\u003ePeriprocedural Complications\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary Access After TAVR\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eTranscatheter Mitral Valve Intervention\u003c\/h3\u003e\r\nTopics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMitral Regurgitation\u003c\/li\u003e\r\n \t\u003cli\u003eTranscatheter Mitral Valve Replacement\u003c\/li\u003e\r\n \t\u003cli\u003eMitral Transcatheter Edge-to-Edge Repair\u003c\/li\u003e\r\n \t\u003cli\u003eValve Anatomy\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Selection\u003c\/li\u003e\r\n \t\u003cli\u003eImaging Guidance\u003c\/li\u003e\r\n \t\u003cli\u003eProcedural Outcomes\u003c\/li\u003e\r\n \t\u003cli\u003ePostprocedural Monitoring\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eEmerging Structural Heart Technologies\u003c\/h3\u003e\r\nThe program examines research involving newer cardiovascular devices and evolving transcatheter interventions.\r\n\r\nRelevant areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eStructural Heart Innovation\u003c\/li\u003e\r\n \t\u003cli\u003eTranscatheter Valve Development\u003c\/li\u003e\r\n \t\u003cli\u003eMinimally Invasive Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eAdvanced Imaging\u003c\/li\u003e\r\n \t\u003cli\u003eProcedural Safety\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Outcomes\u003c\/li\u003e\r\n \t\u003cli\u003eDevice Research\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eSession III – Peripheral Vascular Intervention\u003c\/h2\u003e\r\nThe Peripheral Track focuses on endovascular approaches to vascular disease.\r\n\u003ch3\u003ePeripheral Artery Disease\u003c\/h3\u003e\r\nImportant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003ePeripheral Artery Disease\u003c\/li\u003e\r\n \t\u003cli\u003eLower Extremity Arterial Disease\u003c\/li\u003e\r\n \t\u003cli\u003eClaudication\u003c\/li\u003e\r\n \t\u003cli\u003eEndovascular Revascularization\u003c\/li\u003e\r\n \t\u003cli\u003eVascular Access\u003c\/li\u003e\r\n \t\u003cli\u003eBalloon Angioplasty\u003c\/li\u003e\r\n \t\u003cli\u003eStenting\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Outcomes\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eCritical Limb-Threatening Ischemia\u003c\/h3\u003e\r\nExamines complex vascular disease involving severe limb ischemia.\r\n\r\nRelevant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCritical Limb-Threatening Ischemia\u003c\/li\u003e\r\n \t\u003cli\u003eLimb Salvage\u003c\/li\u003e\r\n \t\u003cli\u003eEndovascular Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eArterial Revascularization\u003c\/li\u003e\r\n \t\u003cli\u003eDeep Vein Arterialization\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Selection\u003c\/li\u003e\r\n \t\u003cli\u003eWound Healing\u003c\/li\u003e\r\n \t\u003cli\u003eFunctional Outcomes\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003ePulmonary Embolism Intervention\u003c\/h3\u003e\r\nThe scientific program includes research involving catheter-based treatment of pulmonary embolism.\r\n\r\nRelevant themes include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003ePulmonary Embolism\u003c\/li\u003e\r\n \t\u003cli\u003eMechanical Thrombectomy\u003c\/li\u003e\r\n \t\u003cli\u003eAspiration Thrombectomy\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Risk\u003c\/li\u003e\r\n \t\u003cli\u003eProcedural Safety\u003c\/li\u003e\r\n \t\u003cli\u003eHemodynamic Outcomes\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Selection\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eSession IV – Congenital Heart Intervention\u003c\/h2\u003e\r\nThe Congenital Track reviews catheter-based cardiovascular interventions in patients with congenital heart disease.\r\n\r\nImportant subjects include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCongenital Heart Disease\u003c\/li\u003e\r\n \t\u003cli\u003ePediatric Cardiac Intervention\u003c\/li\u003e\r\n \t\u003cli\u003eStructural Congenital Defects\u003c\/li\u003e\r\n \t\u003cli\u003eCatheter-Based Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eHemodynamic Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eImaging Guidance\u003c\/li\u003e\r\n \t\u003cli\u003eDevice Selection\u003c\/li\u003e\r\n \t\u003cli\u003eProcedural Planning\u003c\/li\u003e\r\n \t\u003cli\u003eLong-Term Follow-Up\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe program is relevant to pediatric and adult congenital heart disease specialists.\r\n\u003ch2\u003eSession V – Interventional Leadership\u003c\/h2\u003e\r\nThe Interventional Leadership Track examines the professional and organizational responsibilities of cardiovascular intervention specialists.\r\n\r\nImportant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003ePhysician Leadership\u003c\/li\u003e\r\n \t\u003cli\u003eCareer Development\u003c\/li\u003e\r\n \t\u003cli\u003eProfessional Collaboration\u003c\/li\u003e\r\n \t\u003cli\u003eTeam Communication\u003c\/li\u003e\r\n \t\u003cli\u003eWorkplace Wellbeing\u003c\/li\u003e\r\n \t\u003cli\u003eFinancial and Contractual Considerations\u003c\/li\u003e\r\n \t\u003cli\u003eHealthcare Reimbursement\u003c\/li\u003e\r\n \t\u003cli\u003eProfessional Transitions\u003c\/li\u003e\r\n \t\u003cli\u003eMentorship\u003c\/li\u003e\r\n \t\u003cli\u003eCareer Sustainability\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe track recognizes that effective cardiovascular care requires both procedural expertise and strong professional leadership.\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eLate-Breaking Clinical Trials and Featured Research\u003c\/h1\u003e\r\nThe following examples are confirmed presentations from the original 2026 scientific meeting. They are not a verified inventory of recordings included in the MedicalAmboss package.\r\n\u003ch2\u003eLate-Breaking Clinical Trials – Thursday, April 23, 2026\u003c\/h2\u003e\r\n\u003ch3\u003eAltaValve Early Feasibility Study: One-Year Outcomes With Atrial Fixation Transcatheter Mitral Valve Replacement\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Konstantinos Voudris, MD, PhD, FSCAI\r\n\r\nReviews research involving atrial fixation transcatheter mitral valve replacement.\r\n\r\nThe study is relevant to:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMitral Valve Disease\u003c\/li\u003e\r\n \t\u003cli\u003eTranscatheter Mitral Valve Replacement\u003c\/li\u003e\r\n \t\u003cli\u003eStructural Heart Devices\u003c\/li\u003e\r\n \t\u003cli\u003eEarly Feasibility Research\u003c\/li\u003e\r\n \t\u003cli\u003eProcedural Outcomes\u003c\/li\u003e\r\n \t\u003cli\u003eOne-Year Follow-Up\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eCan Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock (CERAMICS)\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Babar B. Basir, DO, FSCAI\r\n\r\nExamines research on cardiogenic shock management in patients with acute myocardial infarction.\r\n\r\nImportant areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAcute Myocardial Infarction\u003c\/li\u003e\r\n \t\u003cli\u003eCardiogenic Shock\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Escalation\u003c\/li\u003e\r\n \t\u003cli\u003eMechanical Circulatory Support\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Outcomes\u003c\/li\u003e\r\n \t\u003cli\u003eMortality Risk\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003ePROMISE III: 6-Month Clinical and Quality of Life Outcomes in CLTI Patients Treated With Transcatheter Arterialization of the Deep Veins\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Mehdi H. Shishehbor, DO, MPH, PhD, FSCAI\r\n\r\nReviews clinical and quality-of-life outcomes involving transcatheter deep vein arterialization in critical limb-threatening ischemia.\r\n\r\nRelevant concepts include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCritical Limb-Threatening Ischemia\u003c\/li\u003e\r\n \t\u003cli\u003eDeep Vein Arterialization\u003c\/li\u003e\r\n \t\u003cli\u003eLimb Salvage\u003c\/li\u003e\r\n \t\u003cli\u003eEndovascular Intervention\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Follow-Up\u003c\/li\u003e\r\n \t\u003cli\u003eQuality of Life\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eSirolimus Eluting Balloons for Patients With Acute Coronary Syndrome—Evidence From the SELUTION DeNovo Trial\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Christian Spaulding, MD, PhD\r\n\r\nExamines evidence involving sirolimus-eluting balloon therapy in acute coronary syndrome.\r\n\r\nRelevant subjects include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAcute Coronary Syndrome\u003c\/li\u003e\r\n \t\u003cli\u003eDrug-Eluting Balloons\u003c\/li\u003e\r\n \t\u003cli\u003eSirolimus\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary Intervention\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Trial Evidence\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Outcomes\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eFeatured Clinical Science – Friday, April 24, 2026\u003c\/h2\u003e\r\n\u003ch3\u003e6-Month Outcomes of the CARPOOL Study: Radial-to-Peripheral vs. Femoral Access in Lower Extremity PAD Revascularization\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Sameh Sayfo, MD, MBA, FSCAI\r\n\r\nReviews alternative vascular access approaches for lower extremity peripheral artery disease revascularization.\r\n\u003ch3\u003eClinical Outcomes of Blood Return During Continuous Aspiration Mechanical Thrombectomy for Pulmonary Embolism: ENGULF Analysis\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Andrew J. Klein, MD, FSCAI\r\n\r\nExamines mechanical thrombectomy research and procedural considerations in pulmonary embolism intervention.\r\n\u003ch3\u003eElectronic Provider Notification Mitigates Age Disparities in the Treatment of Severe Aortic Stenosis: Insights From the DETECT AS Trial\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Sammy Elmariah, MD, FSCAI\r\n\r\nReviews research addressing treatment disparities and clinical notification systems in severe aortic stenosis.\r\n\u003ch3\u003eLipoprotein(a) Identifies Residual Cardiovascular Risk in NIH Randomized Trials\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Subhash Banerjee, MD, FSCAI\r\n\r\nExamines the relationship between lipoprotein(a) and residual cardiovascular risk.\r\n\u003ch3\u003eNet Clinical Outcomes of Clopidogrel vs. Aspirin Monotherapy After Coronary Stenting Across Bleeding Risk and Procedural Complexity\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Hao-Yu Wang, MD, PhD, FSCAI\r\n\r\nReviews antiplatelet therapy research following coronary stent implantation.\r\n\u003ch3\u003eNorth American COVID-19 Myocardial Infarction (NACMI) Registry: One-Year Follow-Up\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Payam Dehghani, MD\r\n\r\nExamines follow-up research involving myocardial infarction and COVID-19.\r\n\u003ch3\u003eOutcomes of Mitral Transcatheter Edge-to-Edge Repair in Patients With Mitral Annular Calcification\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Karim Al-Azizi, MD, FSCAI\r\n\r\nReviews clinical outcomes following mitral transcatheter edge-to-edge repair in patients with mitral annular calcification.\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eFeatured Keynote and Scientific Lectures\u003c\/h2\u003e\r\n\u003ch3\u003eMedical Device Development: A Journey to Transform Patient's Lives\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Martin B. Leon, MD\r\n\r\nThis keynote explores cardiovascular device innovation and the development of technologies intended to improve patient care.\r\n\r\nImportant themes include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMedical Device Development\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Research\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Innovation\u003c\/li\u003e\r\n \t\u003cli\u003eDevice Evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eTranslation of Research\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Outcomes\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eWhat I Have Learned from Examination of Cases of Sudden Coronary Death\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Renu Virmani, MD\r\n\r\nThis Founders Lecture reviews insights from pathological examination of sudden coronary death.\r\n\r\nRelevant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCoronary Pathology\u003c\/li\u003e\r\n \t\u003cli\u003eAtherosclerosis\u003c\/li\u003e\r\n \t\u003cli\u003ePlaque Morphology\u003c\/li\u003e\r\n \t\u003cli\u003eSudden Cardiac Death\u003c\/li\u003e\r\n \t\u003cli\u003eVascular Disease\u003c\/li\u003e\r\n \t\u003cli\u003eClinical-Pathological Correlation\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eHow Vascular Biology and Quantum Dynamics Drove a Revolution in Cardiovascular Sciences \u0026amp; Intervention\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Elazer R. Edelman, MD, PhD\r\n\r\nThe Hildner Lecture examines the relationship between vascular science and developments in cardiovascular intervention.\r\n\u003ch3\u003eGetting the Gang Back Together\u003c\/h3\u003e\r\n\u003cstrong\u003eModerator:\u003c\/strong\u003e Thomas J. Forbes, MD\r\n\r\n\u003cstrong\u003ePanelists:\u003c\/strong\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eZahid C. Amin, MD, MSCAI\u003c\/li\u003e\r\n \t\u003cli\u003eLee N. Benson, MD, MSCAI\u003c\/li\u003e\r\n \t\u003cli\u003eThomas E. Fagan, MD, MSCAI\u003c\/li\u003e\r\n \t\u003cli\u003eFrank F. Ing, MD, MSCAI\u003c\/li\u003e\r\n \t\u003cli\u003eLarry A. Latson, MD, MSCAI\u003c\/li\u003e\r\n \t\u003cli\u003ePhillip Moore, MD\u003c\/li\u003e\r\n \t\u003cli\u003eJulie A. Vincent, MD, FSCAI\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe Mullins Lecture brings together senior experts for a discussion of congenital and interventional cardiology.\r\n\u003ch3\u003eMolecular Engineering to Bedside Innovation\u003c\/h3\u003e\r\n\u003cstrong\u003eModerator:\u003c\/strong\u003e Sahil A. Parikh, MD, FSCAI\r\n\r\n\u003cstrong\u003ePanelists:\u003c\/strong\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eElazer R. Edelman, MD, PhD\u003c\/li\u003e\r\n \t\u003cli\u003eMartin B. Leon, MD\u003c\/li\u003e\r\n \t\u003cli\u003eRenu Virmani, MD\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThis scientific roundtable explores the relationship between molecular engineering, cardiovascular research, innovation, and clinical implementation.\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eAdditional Scientific Activities\u003c\/h2\u003e\r\nThe original SCAI 2026 program also featured:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eLive Cardiovascular Cases\u003c\/li\u003e\r\n \t\u003cli\u003eHands-On Workshops\u003c\/li\u003e\r\n \t\u003cli\u003eEndovascular Practicums\u003c\/li\u003e\r\n \t\u003cli\u003eLearning Laboratories\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Presentations\u003c\/li\u003e\r\n \t\u003cli\u003ePoster Abstracts\u003c\/li\u003e\r\n \t\u003cli\u003eInternational Case Exchanges\u003c\/li\u003e\r\n \t\u003cli\u003eFellows Summit for Complex Cases\u003c\/li\u003e\r\n \t\u003cli\u003eSCAI Women in Innovations\u003c\/li\u003e\r\n \t\u003cli\u003eSCAI Science and Practice\u003c\/li\u003e\r\n \t\u003cli\u003eProfessional Networking\u003c\/li\u003e\r\n \t\u003cli\u003eScientific Research Discussions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThese activities represent the scope of the original conference and are not automatically included in the separate educational file collection.\r\n\u003ch2\u003eMajor Topics Covered\u003c\/h2\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eSCAI Scientific Sessions 2026\u003c\/li\u003e\r\n \t\u003cli\u003eSociety for Cardiovascular Angiography \u0026amp; Interventions\u003c\/li\u003e\r\n \t\u003cli\u003eInterventional Cardiology\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary Intervention\u003c\/li\u003e\r\n \t\u003cli\u003eComplex PCI\u003c\/li\u003e\r\n \t\u003cli\u003ePercutaneous Coronary Intervention\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary Artery Disease\u003c\/li\u003e\r\n \t\u003cli\u003eAcute Coronary Syndrome\u003c\/li\u003e\r\n \t\u003cli\u003eCardiogenic Shock\u003c\/li\u003e\r\n \t\u003cli\u003eMechanical Circulatory Support\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary Imaging\u003c\/li\u003e\r\n \t\u003cli\u003eIntravascular Ultrasound\u003c\/li\u003e\r\n \t\u003cli\u003eOptical Coherence Tomography\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary Physiology\u003c\/li\u003e\r\n \t\u003cli\u003eFractional Flow Reserve\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary Calcification\u003c\/li\u003e\r\n \t\u003cli\u003eAtherectomy\u003c\/li\u003e\r\n \t\u003cli\u003eIntravascular Lithotripsy\u003c\/li\u003e\r\n \t\u003cli\u003eDrug-Eluting Stents\u003c\/li\u003e\r\n \t\u003cli\u003eDrug-Coated Balloons\u003c\/li\u003e\r\n \t\u003cli\u003eIn-Stent Restenosis\u003c\/li\u003e\r\n \t\u003cli\u003eAntiplatelet Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eStructural Heart Intervention\u003c\/li\u003e\r\n \t\u003cli\u003eTAVR\u003c\/li\u003e\r\n \t\u003cli\u003eTMVR\u003c\/li\u003e\r\n \t\u003cli\u003eMitral TEER\u003c\/li\u003e\r\n \t\u003cli\u003eAortic Stenosis\u003c\/li\u003e\r\n \t\u003cli\u003eMitral Regurgitation\u003c\/li\u003e\r\n \t\u003cli\u003ePeripheral Artery Disease\u003c\/li\u003e\r\n \t\u003cli\u003eCritical Limb-Threatening Ischemia\u003c\/li\u003e\r\n \t\u003cli\u003eEndovascular Revascularization\u003c\/li\u003e\r\n \t\u003cli\u003eDeep Vein Arterialization\u003c\/li\u003e\r\n \t\u003cli\u003ePulmonary Embolism\u003c\/li\u003e\r\n \t\u003cli\u003eMechanical Thrombectomy\u003c\/li\u003e\r\n \t\u003cli\u003eCongenital Heart Intervention\u003c\/li\u003e\r\n \t\u003cli\u003ePediatric Interventional Cardiology\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Devices\u003c\/li\u003e\r\n \t\u003cli\u003eProcedural Complications\u003c\/li\u003e\r\n \t\u003cli\u003eLate-Breaking Clinical Trials\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Research\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Case Discussions\u003c\/li\u003e\r\n \t\u003cli\u003eInterventional Leadership\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eCoronary Artery Disease and Complex PCI\u003c\/h2\u003e\r\nPercutaneous coronary intervention remains an important treatment option for selected patients with coronary artery disease.\r\n\r\nComplex PCI may involve challenging coronary anatomy, severe calcification, bifurcation lesions, chronic total occlusions, restenosis, and hemodynamic instability.\r\n\r\nThe SCAI 2026 educational program emphasizes procedural planning, appropriate imaging, device selection, complication management, and evidence-based intervention.\r\n\u003ch2\u003eStructural Heart Disease and Transcatheter Therapy\u003c\/h2\u003e\r\nStructural heart interventions continue to evolve through advances in transcatheter valve replacement, valve repair, cardiovascular imaging, and device development.\r\n\r\nThe program includes scientific discussions relevant to aortic and mitral valve disease, patient selection, structural heart procedures, and clinical outcomes.\r\n\u003ch2\u003ePeripheral Vascular Disease and Limb Preservation\u003c\/h2\u003e\r\nPeripheral artery disease and critical limb-threatening ischemia present important challenges in cardiovascular care.\r\n\r\nEndovascular technologies and revascularization approaches are evaluated through clinical trials and procedural research.\r\n\r\nThe program provides educational perspectives on the diagnosis, treatment, and outcomes of complex peripheral vascular disease.\r\n\u003ch2\u003eCardiogenic Shock and Mechanical Circulatory Support\u003c\/h2\u003e\r\nCardiogenic shock is associated with significant clinical risk and requires coordinated assessment and treatment.\r\n\r\nThe curriculum examines emerging research and interventional approaches intended to improve care in patients with acute myocardial infarction and severe hemodynamic compromise.\r\n\u003ch2\u003eCardiovascular Clinical Trials and Evidence-Based Practice\u003c\/h2\u003e\r\nLate-breaking scientific research is a major component of SCAI Scientific Sessions.\r\n\r\nThe 2026 program includes presentations examining coronary devices, structural interventions, peripheral vascular procedures, cardiogenic shock, antiplatelet therapy, and cardiovascular outcomes.\r\n\r\nClinicians are encouraged to evaluate trial design, patient populations, clinical endpoints, study limitations, and implications for practice.\r\n\u003ch2\u003eProcedural Education and Complex Cases\u003c\/h2\u003e\r\nThe original conference includes practical educational activities involving advanced procedures, difficult cardiovascular anatomy, clinical case exchanges, and complication management.\r\n\r\nThese activities support the integration of clinical evidence with procedural expertise and multidisciplinary decision-making.\r\n\u003ch2\u003eInterventional Cardiology Leadership and Collaboration\u003c\/h2\u003e\r\nInterventional cardiovascular care depends on effective communication among physicians, nurses, technologists, imaging specialists, researchers, and other healthcare professionals.\r\n\r\nThe leadership curriculum addresses professional growth, team collaboration, career development, and challenges affecting contemporary cardiovascular practice.\r\n\u003ch2\u003eProgram Leadership\u003c\/h2\u003e\r\n\u003ch3\u003eSahil A. Parikh, MD, FSCAI\u003c\/h3\u003e\r\n\u003cstrong\u003eSCAI 2026 Program Chair\u003c\/strong\u003e\r\n\u003ch3\u003eAndrew J. Klein, MD, FSCAI\u003c\/h3\u003e\r\n\u003cstrong\u003eAssociate Program Chair\u003c\/strong\u003e\r\n\u003ch3\u003eFrederick G. P. Welt, MD, MSc, FSCAI\u003c\/h3\u003e\r\n\u003cstrong\u003eAssistant Program Chair\u003c\/strong\u003e\r\n\r\nThe original conference brought together international faculty and research contributors across multiple cardiovascular subspecialties.\r\n\u003ch2\u003eContinuing Medical Education\u003c\/h2\u003e\r\nThe original SCAI 2026 Scientific Sessions \u0026amp; CAIC-ACCI Summit provided educational activities for interventional cardiovascular professionals.\r\n\r\nAny official continuing medical education credits or certificates are governed by the accreditation and participation requirements of the organizer.\r\n\u003ch3\u003eImportant CME Notice\u003c\/h3\u003e\r\nPurchasing separately distributed educational files from MedicalAmboss does not provide:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eOfficial SCAI CME Credits\u003c\/li\u003e\r\n \t\u003cli\u003eOfficial Completion Certificates\u003c\/li\u003e\r\n \t\u003cli\u003eSCAI Conference Registration\u003c\/li\u003e\r\n \t\u003cli\u003eLive Conference Attendance\u003c\/li\u003e\r\n \t\u003cli\u003eSCAI Membership\u003c\/li\u003e\r\n \t\u003cli\u003eOfficial Conference Library Access\u003c\/li\u003e\r\n \t\u003cli\u003ePublisher Platform Accounts\u003c\/li\u003e\r\n \t\u003cli\u003ePublisher-Hosted Extras\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eWhy This Course Is Relevant\u003c\/h2\u003e\r\nThe \u003cstrong\u003eSCAI Scientific Sessions 2026 – Videos + PPTs\u003c\/strong\u003e collection is associated with an important international educational program in interventional cardiology.\r\n\r\nThe original conference addresses major scientific and procedural developments across coronary, peripheral, structural, and congenital heart interventions.\r\n\r\nIts educational scope encompasses clinical trials, evolving cardiovascular devices, imaging, procedural decision-making, complex cases, and professional collaboration.\r\n\r\nThe program is particularly relevant to interventional cardiologists, cardiology fellows, structural heart specialists, peripheral vascular interventionists, congenital heart specialists, and catheterization laboratory professionals.\r\n\u003ch2\u003eOfficial Program Reference and MedicalAmboss Purchase Scope\u003c\/h2\u003e\r\n\u003cstrong\u003eOfficial SCAI 2026 Conference:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/www.scai.org\/education-and-events\/events-schedule\/scai-2026-scientific-sessions-caic-acci-summit\" data-rich-text-autolink=\"\"\u003ehttps:\/\/www.scai.org\/education-and-events\/events-schedule\/scai-2026-scientific-sessions-caic-acci-summit\u003c\/a\u003e\r\n\r\n\u003cstrong\u003eOfficial Scientific Program:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/www.scai.org\/education-and-events\/events-schedule\/scai-2026-scientific-sessions-caic-acci-summit\/program-0\" data-rich-text-autolink=\"\"\u003ehttps:\/\/www.scai.org\/education-and-events\/events-schedule\/scai-2026-scientific-sessions-caic-acci-summit\/program-0\u003c\/a\u003e\r\n\r\n\u003cstrong\u003eOfficial Late-Breaking Research:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/www.scai.org\/education-and-events\/events-schedule\/scai-2026-scientific-sessions-caic-acci-summit\/late-breaking\" data-rich-text-autolink=\"\"\u003ehttps:\/\/www.scai.org\/education-and-events\/events-schedule\/scai-2026-scientific-sessions-caic-acci-summit\/late-breaking\u003c\/a\u003e\r\n\r\n\u003cstrong\u003eMedicalAmboss Product:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/medicalamboss.com\/product\/society-for-cardiovascular-angiography-interventions-scientific-sessions-2026\/\" data-rich-text-autolink=\"\"\u003ehttps:\/\/medicalamboss.com\/product\/society-for-cardiovascular-angiography-interventions-scientific-sessions-2026\/\u003c\/a\u003e\r\n\r\nThese references describe the original scientific meeting, its clinical tracks, featured research, program leadership, and educational activities.\r\n\r\nThey do not establish the exact inventory of video and PowerPoint files included in this MedicalAmboss listing.\r\n\r\n\u003cstrong\u003eMedicalAmboss File Scope:\u003c\/strong\u003e This listing describes the educational subject matter for reference. Provider registration, live attendance, streaming-platform access, CME or other credit, certificates, memberships, apps, accounts, and publisher-hosted extras are not included unless explicitly listed as store files.\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eShort Description\u003c\/h2\u003e\r\n\u003cstrong\u003eSCAI Scientific Sessions 2026 – Videos + PPTs\u003c\/strong\u003e provides educational content associated with the Society for Cardiovascular Angiography \u0026amp; Interventions 2026 scientific meeting in Montreal, Canada.\r\n\r\nHeld April 23–25, 2026, the original international conference covers complex coronary intervention, advanced PCI, structural heart disease, transcatheter valve therapy, peripheral vascular intervention, congenital heart disease, cardiogenic shock, procedural innovation, and late-breaking clinical trials.","brand":"Amboss","offers":[{"title":"Default Title","offer_id":67982435745946,"sku":"MED-AMB10544","price":56.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/macs-0efe51bcb5-50447-51098-57249d5943b5e1d9acc6.jpg?v=1793146375","url":"https:\/\/ambosscourse.com\/products\/wc-0efe51bcb5f34c14-50447","provider":"Amboss","version":"1.0","type":"link"}